AI-Designed Vaccine Undergoes Human Trials

A team of researchers from the United Kingdom has developed the first vaccine designed entirely by artificial intelligence (AI) and has successfully commenced human trials. The vaccine is claimed to provide broader protection against various mutating viruses and even possesses the potential to protect against new viruses in the future.

This research is led by scientists from the University of Cambridge and the University of Southampton. According to the researchers, the development of this vaccine is crucial because current systems remain reactive and struggle to keep pace with the rate of viral evolution.

“Viruses such as Influenza, Coronavirus, and Ebola continue to evolve. By the time vaccines are available and distributed, they are often no longer fully compatible with the circulating virus strains,” said researcher Prof. Saul Faust, as reported by Euro News.

In recent years, several outbreaks caused by betacoronaviruses have occurred, including the Covid-19 pandemic. The continuous circulation of these viruses has triggered mutations and the emergence of various new variants.

To address this challenge, researchers have developed a new type of vaccine designed to provide long-term protection against various viruses within a single group, such as the Ebola virus and the coronavirus group, even as these viruses undergo continuous evolution.

Lead researcher Prof. Jonathan Heeney, from the Zoonosis Virus Laboratory at the University of Cambridge, stated that this technology could shift the paradigm of vaccine development. “We have transformed vaccine development from being reactive to being future-ready. We are overcoming the limitations of traditional vaccines that offer limited protection. Consequently, we will no longer need to constantly chase circulating virus variants and update vaccines to keep up with them,” he said.

To create this vaccine, the research team utilised active components designed entirely by AI, known as “super-antigens”. The vaccine uses computer-designed proteins that mimic common characteristics shared by many coronaviruses, rather than targeting one specific strain. This approach can trigger the immune system to fight various pathogens that possess the same fundamental characteristics.